In people with Type 1 Diabetes, self-monitoring of BLOOD GLUCOSE (SMBG) is an integral part of treatment. SMBG can play an important role in improving metabolic control in patients with diabetes. It is recommended for patients treated with insulin and is desirable for all patients with diabetes. Judicious use of SMBG data can help to improve glycemic control, select an anti-diabetic regimen, and provide powerful feedback to patients wishing to improve metabolic control. Among patients with type 1 diabetes, SMBG has been associated with improved health outcomes. Self monitoring of BLOOD GLUCOSE is an opportunity for people with diabetes to take control of their health. The main goal of treatment is to keep BLOOD GLUCOSE levels in the normal or near-normal range. Monitoring BLOOD GLUCOSE levels is one of the best ways of determining how well a diabetes treatment plan is working. Adjusted for age, gender, diabetes duration, year of treatment, insulin regimen, insulin dose, BMI-SDS, and center difference, SMBG frequency was significantly associated with better metabolic control with a drop of HbA1c of 0.20% for one additional SMBG per day. However, some studies showed that increasing the SMBG frequency above 5/d did not result in further improvement of metabolic control. Further, costs associated with SMBG are high and rising steadily due to the increasing prevalence of diabetes and higher rates of self-monitoring. Most experts agree that insulintreated patients should monitor BLOOD GLUCOSE at least four times a day, most commonly fasting, before meals, and before bed.